M&A

Pressing for direct negotiations, Takeda adds cash to a meatier $63B bid to buy Shire
Pressing for direct negotiations, Takeda adds cash to a meatier $63B bid to buy Shire
Endpoints
Shire
Takeda
M&A
Flag link:
Allergan will not bid for Shire: Sources
Allergan will not bid for Shire: Sources
CNBC
Allergan
Shire
M&A
Takeda
Flag link:
Procter & Gamble Acquires Consumer Health Unit of Merck KGaA for $4.2B
Procter & Gamble Acquires Consumer Health Unit of Merck KGaA for $4.2B
CP Wire
Procter & Gamble
Merck KGaA
M&A
consumer health
Flag link:
A bidding war is brewing over $50 billion drugmaker Shire
A bidding war is brewing over $50 billion drugmaker Shire
Business Insider
Shire
Takeda
Allergan
M&A
Flag link:
Takeda makes $61 billion bid for drugmaker Shire: sources
Takeda makes $61 billion bid for drugmaker Shire: sources
Reuters
Takeda
Shire
M&A
Flag link:
Shire's oncology exit weighs on potential Takeda bid
Shire's oncology exit weighs on potential Takeda bid
Biopharma Dive
Shire
oncology
Takeda
M&A
Servier
Flag link:
[video]Did Novartis Overpay for AveXis?
[video]Did Novartis Overpay for AveXis?
Motley Fool
Novartis
AveXis
gene therapy
M&A
Flag link:
Boston Scientific acquires NVision Medical in $275m deal
Boston Scientific acquires NVision Medical in $275m deal
Mass Device
Boston Scientific
NVision Medical
M&A
devices
diagnostics
ovarian cancer
Flag link:
Advent Is Said to Near Deal to Acquire Sanofi Generics Unit
Advent Is Said to Near Deal to Acquire Sanofi Generics Unit
Bloomberg
Advent International
Sanofi
generics
M&A
Flag link:
Servier buys Shire’s oncology unit for $2.4B in the run-up to Takeda’s final buyout offer — if it makes one
Servier buys Shire’s oncology unit for $2.4B in the run-up to Takeda’s final buyout offer — if it makes one
Endpoints
Servier
Shire
Takeda
M&A
oncology
Flag link:
3 Biotech Stocks That Soared This Week
3 Biotech Stocks That Soared This Week
Motley Fool
AveXis
Abeona Therapeutics
Spectrum Pharmaceuticals
Novartis
M&A
poziotinib
EB-101
Flag link:
Merck KGaA Consumer Unit Is a Deal Too Far for Mylan: Gadfly
Merck KGaA Consumer Unit Is a Deal Too Far for Mylan: Gadfly
Washington Post, DC
Merck KGaA
consumer health
M&A
Mylan Labs
Flag link:
Pfizer's Deal Potential Doesn't Stop at Bristol-Myers
Pfizer's Deal Potential Doesn't Stop at Bristol-Myers
Bloomberg
Pfizer
M&A
Bristol-Myers Squibb
Celgene
Eli Lilly
AstraZeneca
Flag link:
Mylan seeks deal for German Merck's consumer products unit - sources
Mylan seeks deal for German Merck's consumer products unit - sources
Yahoo/Reuters
Mylan Labs
Merck KGaA
consumer health
M&A
Flag link:
Trust me, Pfizer isn't interested in buying BMS, analyst says—at least not yet
Trust me, Pfizer isn't interested in buying BMS, analyst says—at least not yet
Fierce Pharma
Pfizer
M&A
Ian Read
Bristol-Myers Squibb
Flag link:
Alexion buying Swedish biotech for $855 million to broaden rare disease pipeline
Alexion buying Swedish biotech for $855 million to broaden rare disease pipeline
Stat
Alexion
WIlson Therapeutics
M&A
Rare Diseases
Flag link:
Teva's M&A-gone-wrong lawsuit over Rimsa deal nets a paltry settlement
Teva's M&A-gone-wrong lawsuit over Rimsa deal nets a paltry settlement
Fierce Pharma
Teva Pharmaceutical
generics
fraud
Rimsa
M&A
Flag link:
Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: 'A Journey To Focus On Data And Digital'
Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: 'A Journey To Focus On Data And Digital'
Forbes
Novartis
Vas Narasimhan
M&A
gene therapy
AveXis
Flag link:
Celgene on biotech hunt with Agios, Jounce in crosshairs: FT
Celgene on biotech hunt with Agios, Jounce in crosshairs: FT
Fierce Biotech
Celgene
M&A
Agios Pharmaceuticals
Jounce Therapeutics
Flag link:
Biogen faces increased 'pressure' after AveXis buyout by Novartis
Biogen faces increased 'pressure' after AveXis buyout by Novartis
Marketwatch
Novartis
AveXis
Biogen
SMA
M&A
AVXS-1-1
Spinraza
Flag link:

Pages